Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director Shareholding

18th Mar 2014 13:55

RNS Number : 5915C
ABCAM Plc
18 March 2014
 



For immediate release

18 March 2014

 

ABCAM PLC

("Abcam" or "the Company")

Director's dealings

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, has today been notified that on 17 March 2014, Jonathan Milner, a Director of the Company, transferred 540,000 Ordinary Shares of 0.2 pence each in the Company ("Ordinary Shares") for nil consideration to a charitable trust of which he is a trustee.

 

Following this transfer, Dr Milner's total interest in the Company remains unchanged at 27,655,855 Ordinary Shares of 0.2 pence each, representing approximately 13.8% of the Company's issued share capital. The total interest is constituted as follows:

 

Beneficial Interest

 

27,060,355

Non-Beneficial Interest:

595,500

 

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

 

Numis Securities - Nominated Adviser & Joint Broker

+ 44 (0) 20 7260 1000

Michael Meade - Nominated Adviser

James Black - Corporate Broking

 

Peel Hunt LLP - Joint Broker

+ 44 (0) 20 7418 8900

Clare Terlouw / Jock Maxwell MacDonald

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

Notes for editors:

About Abcam plc

Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.

Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 129,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).

To find out more, please visit www.abcam.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSJPMJTMBABBII

Related Shares:

ABC.L
FTSE 100 Latest
Value8,809.74
Change53.53